Today: 29 April 2026
NAB share price drops as ASX selloff spooks bank stocks — what to watch before Monday
7 February 2026
1 min read

NAB share price drops as ASX selloff spooks bank stocks — what to watch before Monday

SYDNEY, Feb 7, 2026, 16:48 AEDT — Market shut for the day.

  • NAB slipped in the last session, dragged down by a wave of selling that hit Australian equities.
  • Investors are trying to gauge the impact of higher rates on mortgage pricing—and what that means for borrower stress.
  • Bank updates coming up later this month look set to put sentiment to the test in the near term.

Shares of National Australia Bank Ltd (NAB.AX) closed at A$43.36, slipping 1.57%. Australian stocks wrapped up the week on a sour note, putting investors on edge for Monday.

The market’s closed for the weekend, leaving traders to wonder if Friday’s risk-off turn was just a brief shakeout—or if something stickier is brewing. In Australia, it’s often the banks at the core of that debate.

NAB has a rate change on its hands. Starting Feb. 13, variable home loan rates are going up by 25 basis points, or a quarter of a percentage point, the bank announced. That follows the Reserve Bank of Australia’s move to push the cash rate up to 3.85%.

Australian shares tumbled Friday, the ASX 200 dropping 2% as losses hit every sector, ABC reported, citing LSEG figures. “Panic is spreading,” MooMoo Australia analyst Michael McCarthy told ABC News, noting that the sight of “so many markets falling at the same time is unnerving investors.” ABC News

Pressure hit the major banks. Commonwealth Bank of Australia (CBA.AX) edged down 0.23%, closing at A$158.91 last session. The rest of the big lenders also lost ground.

Elsewhere on the corporate front, NAB plans to introduce video “everyday banking” appointments starting in March, adding to its in-branch options. “We know time is precious,” retail banking executive Paul Carter said in a statement. NAB News

Traders find themselves circling back to a familiar concern: margins and credit. On one hand, higher rates have the potential to boost banks’ net interest margin—the difference between loan earnings and deposit costs. On the other, those same increases raise pressure on borrowers, pushing up arrears.

That’s the risk scenario here. Mortgage stress picking up speed beyond what banks have penciled in means more provisions, and whatever lift they get from higher pricing starts to disappear. The rest? Volatile market action fills in the gaps.

NAB’s first-quarter trading update lands Feb. 18. Investors will be watching closely for changes in bad-debt figures, how deposit competition is shaping up, and what’s happening with loan growth.

Stock Market Today

  • Biotech with $277M Cash Says It Can Fund Operations Through 2028
    April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies, essential for market approval and revenue potential. Its financial position is underpinned by regulatory filings, including registration statements on Form S-1, offering transparency for investors assessing risks and opportunities. This solid cash reserve and regulatory progress support confidence in sustained operations and developmental goals over the coming years.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 29.04.2026

29 April 2026
LIVEMarkets rolling coverageStarted: April 29, 2026, 12:00 AM EDTUpdated: April 29, 2026, 2:53 AM EDT Biotech with $277M Cash Says It Can Fund Operations Through 2028 April 29, 2026, 2:48 AM EDT. A biotech company reports having $277 million in cash, stating it can finance its operations through 2028. The firm highlights progress in regulatory milestones, including orphan drug designation and fast track status, which aim to expedite drug approvals for rare diseases. These designations often provide special incentives and faster review processes. The company is advancing clinical trials with key drugs in Phase 2b and planning Phase 3 studies,
AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

AST SpaceMobile Stock’s May 11 Moment: FCC Win Meets BlueBird 7 Reality

29 April 2026
AST SpaceMobile will hold its first-quarter update call on May 11 after winning FCC approval to deploy a 248-satellite constellation for direct-to-device service. Shares fell 6.8% Tuesday, following the loss of its BlueBird 7 satellite in a failed launch. The company expects insurance to cover the loss and is targeting 45 satellites in orbit by end-2026. Investors are watching launch progress and commercial service timing.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand
Previous Story

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

SGX share price dips at week’s end after record profit; what investors watch next
Next Story

SGX share price dips at week’s end after record profit; what investors watch next

Go toTop